# Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

> **NCT00855166** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 182 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Metformin
- **DRUG:** Sitagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00855166
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-06
- **Final completion:** 2011-12
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2013-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00855166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00855166, "Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00855166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*